Pfizer COVID-19 vaccine shows strong effectiveness after six months

Daniel Fowler
April 5, 2021

Six of those cases were confirmed to be of the B.1.351 lineage, which caused concerns when it was first discovered as vaccines were not designed with this mutation in mind.

The early-stage phase I trial will evaluate the vaccine's safety and ability to create an immune response.

The vaccine remains more than 91% effective against disease with any symptoms for six months, the companies said in a statement. "These data also provide the first clinical results that a vaccine can effectively protect against now circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population".

The Pfizer Covid-19 vaccine looks to offer 100% protection against the South African variant, and is mostly likely highly effective against the variant that originated in Brazil, two new studies suggest.

"Our findings extend those from smaller studies reported elsewhere and support a potential strategy of providing a single dose of vaccine to persons with a confirmed prior history of coronavirus infection, along with two doses for people not previously infected", said Susan Cheng, Associate professor at the Cedars-Sinai Medical Centre in California, US. "These data also provide the first clinical results that a vaccine can effectively protect against now circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population". The company submitted updated data to FDA showing how much vaccine can be extracted from each vial using different types of syringes.

U.S. CDC: travel 'low risk' for vaccinated people; not recommending trips
A person is considered fully vaccinated two weeks after receiving the last recommended dose of vaccine. More than 553,000 people have died of the virus in the USA , amid more than 30 million cases.

'The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccine's overall effectiveness'.

USA top infectious diseases doctor Anthony Fauci told Reuters on Thursday that the country may not need AstraZeneca's Covid-19 vaccine even if it wins United States regulatory approval.

"Preliminary data show that the COVID-19 vaccines now available in the United States should provide an adequate degree of protection against SARS-CoV-2 variants", Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, said in the statement.

The efficacy level is slightly down from the 95% number the vaccine first posted in the trial.

Of the total cases, investigators recorded 850 in the placebo group compared with 77 in the vaccine cohort. And the combination of having very high levels of antibodies and persistent levels of protection are the recipe for a very long level of protection against these variants, ' Hensley added.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER